Pleiotropic Effects of Platelet P2Y12 Receptor Inhibitors: Fact or Fiction?

Athanasios      Moulias; Ioanna      Xanthopoulou; Dimitrios      Alexopoulos

doi:10.2174/1381612820666140414211543

Abstract

P2Y₁₂ inhibitors constitute an essential part of the antithrombotic treatment, with proven clinical benefit in acute coronary syndromes and after percutaneous coronary interventions. Substantial evidence has emerged that, apart from their primary antiplatelet action, P2Y₁₂ receptor inhibitors exhibit several off-target effects. In this review, we present the supporting evidence of P2Y₁₂ inhibitors’ pleiotropic actions, discuss their clinical implications and underscore the necessity for further research on this issue.

Keywords: Clopidogrel, off-target effects, pleiotropic, P2Y12 inhibitors, prasugrel, ticagrelor.

« Previous

Rights & Permissions Print Cite

Current Pharmaceutical Design

Title:Pleiotropic Effects of Platelet P2Y₁₂ Receptor Inhibitors: Fact or Fiction?

Volume: 20 Issue: 28

Author(s): Athanasios Moulias, Ioanna Xanthopoulou and Dimitrios Alexopoulos

Affiliation:

Keywords: Clopidogrel, off-target effects, pleiotropic, P2Y12 inhibitors, prasugrel, ticagrelor.

Abstract: P2Y₁₂ inhibitors constitute an essential part of the antithrombotic treatment, with proven clinical benefit in acute coronary syndromes and after percutaneous coronary interventions. Substantial evidence has emerged that, apart from their primary antiplatelet action, P2Y₁₂ receptor inhibitors exhibit several off-target effects. In this review, we present the supporting evidence of P2Y₁₂ inhibitors’ pleiotropic actions, discuss their clinical implications and underscore the necessity for further research on this issue.

Export Options

Export File:

RIS (for EndNote, Reference Manager, ProCite)

BibTeX

Text

Content:

Citation Only

Citation and Abstract

About this article

Cite this article as:

Moulias Athanasios, Xanthopoulou Ioanna and Alexopoulos Dimitrios, Pleiotropic Effects of Platelet P2Y₁₂ Receptor Inhibitors: Fact or Fiction?, Current Pharmaceutical Design 2014; 20 (28) . https://dx.doi.org/10.2174/1381612820666140414211543

DOI https://dx.doi.org/10.2174/1381612820666140414211543	Print ISSN 1381-6128
Publisher Name Bentham Science Publisher	Online ISSN 1873-4286